

(FILE 'USPAT' ENTERED AT 15:47:59 ON 18 SEP 1999)

L1 3124 S DENDRITIC
L2 11 S L1(P) PROSTATE
L3 1 S L1(P) (EXTENDED(W) LIFE(W) SPAN)
L4 111 S L1(P) (FREEZ? OR FROZ? OR CYROPRESERV?)
E MURPHY, GERALD?/IN

SYSTEM:OS - DIALOG OneSearch

File 149:TGG Health&Wellness DB(SM) 1976-1999/Sep W3
(c) 1999 The Gale Group
File 5:Biosis Previews(R) 1969-1999/Aug W2
(c) 1999 BIOSIS
File 73:EMBASE 1974-1999/Sep W1
(c) 1999 Elsevier Science B.V.
File 156:Toxline(R) 1965-1999/Jul
(c) format only 1999 The Dialog Corporation
File 159:Cancerlit 1975-1999/Aug
(c) format only 1999 Dialog Corporation
*File 159: reloaded, note accession numbers changed.
File 155:MEDLINE(R) 1966-1999/Nov W2
(c) format only 1999 Dialog Corporation
*File 155: reloaded, note accession numbers changed.
File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
(c) 1998 Inst for Sci Info
File 76:Life Sciences Collection 1982-1999/Jul
(c) 1999 Cambridge Sci Abs
File 652:US Patents Fulltext 1971-1979
(c) format only 1999 The Dialog Corp.
*File 652: Reassignment data now current through 07/09/99
Reexamination, extension, expiration, reinstatement updated weekly.
File 653:US Pat.Fulltext 1980-1989
(c) format only 1999 Knight-Ridder Info
*File 653: Reassignment data now current through 07/09/99.
Reexamination, extension, expiration, reinstatement updated weekly.
File 654:US Pat.Full. 1990-1999/Sep 14
(c) format only 1999 The Dialog Corp.
*File 654: Reassignment data current through 07/09/99.
File 353:APIPAT 1964-1999/Sep W2
(c) 1999 Elsevier Engineering Info., Inc.
*File 353: !!Abstracts now display in formats AB,7,5,9,29,49!! Output
prices are unchanged. Usage is limited to 2hrs./yr. See HELP NEWS 353
File 357:Derwent Biotechnology Abs 1982-1999/Aug B2
(c) 1999 Derwent Publ Ltd
*File 357: Derwent changes DialUnit pricing from May 1, 1999. See
HELP DERWENT for details.

Set	Items	Description
-----	-------	-------------

?

Set	Items	Description
S1	77	DENDRITIC(5N) PROSTATE
S2	41	RD (unique items)
S3	5	DENDRITIC(5N) (EXTENDED(W) LIFE(W) SPAN OR HALF(W) LIFE)
S4	3	RD (unique items)
S5	138	DENDRITIC(5N) (FREEZ? OR FROZ? OR CRYOPRESERV?)
S6	81	RD (unique items)
S7	3	DENDRITIC(5N) (TURN(W) OVER)

3/7/21 (Item 12 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 1999 BIOSIS. All rts. reserv.

11274539 BIOSIS NO.: 199800055871
Dendritic cell-based immunotherapy of **prostate** cancer.

AUTHOR: Salgaller M L(a); Tjoa B A; Lodge P A; Ragde H; Kenny G; Boynton A;
Murphy G P

AUTHOR ADDRESS: (a)Pacific Northwest Cancer Foundation Northwest Hosp., 120
Northgate Plaza, Suite 205, Seattle, WA, USA

JOURNAL: Critical Reviews in Immunology 18 (1-2):p109-119 1998

ISSN: 1040-8401

DOCUMENT TYPE: Literature Review

RECORD TYPE: Citation

3/7/23 (Item 14 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 1999 BIOSIS. All rts. reserv.

10227661 BIOSIS NO.: 199698682579
Presentation of **prostate** tumor antigens by **dendritic** cells
stimulates T-cell proliferation and cytotoxicity.

AUTHOR: Tjoa Benjamin(a); Boynton Alton; Kenny Gerald; Ragde Haakon;
Misrock S Leslie; Murphy Gerald
AUTHOR ADDRESS: (a)Pacific Northwest Cancer Foundation, Northwest Hospital,
120 Northgate Plaza, Suite 205, Seattle, USA

JOURNAL: Prostate 28 (1):p65-69 1996
ISSN: 0270-4137
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Dendritic cells (DCs) are "professional" antigen-presenting cells capable of stimulating T-cell proliferation and cytotoxicity when loaded with and presenting specific antigens, including tumor antigens. We demonstrated the stimulation of an autologous cytotoxic T-cell response elicited by DC loaded with autologous tumor cell lysate derived from primary prostate tumor. A candidate tumor antigen is prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer patients. We identified a HLA-A2 motif in PSMA, isolated patient DC, loaded peptide into DC, and stimulated autologous T cells to proliferate. The ability to use DC for presentation of either tumor or peptide antigen in an HLA-restricted fashion in order to stimulate T-cell proliferation and cytotoxicity demonstrates the potential of this technology for development of a prostate cancer vaccine.

3/7/24 (Item 15 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 1999 BIOSIS. All rts. reserv.

10016053 BIOSIS NO.: 199598470971
In vitro propagated **dendritic** cells from **prostate** cancer
patients as a component of prostate cancer immunotherapy.

AUTHOR: Tjoa Benjamin(a); Erickson Sheila; Barreni Robert Ii; Ragde Haakon;
Kenny Gerald; Boynton Alton; Murphy Gerald
AUTHOR ADDRESS: (a)Pacific Northwest Cancer Foundation, Cancer Res. Div.,
Northwest Hosp., 120 Northgate Plaza, Sui, USA

JOURNAL: Prostate 27 (2):p63-69 1995
ISSN: 0270-4137
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: T cell-mediated cancer immunotherapy requires efficient antigen-presenting cells. Dendritic cells (DCs) are arguably the most efficient antigen-presenting cells studied to date. Individuals with prostate cancer often undergo various therapies which may compromise their immune system, including the state of their DC precursors. We

report the in vitro propagation of DCs from peripheral blood of patients with prostate cancer, most of whom are in clinical stage D-1 or D-2 and have undergone radiation therapy. After 7 days in culture, the number of DCs recovered were 20-50-fold higher than those isolated directly from peripheral blood. This number is comparable to findings of previous studies with healthy individuals. Cultured patients' DCs were capable of presenting tetanus toxoid to autologous T cells in vitro. Furthermore, T cells from 2 of 4 patients proliferated when cultured with their DCs and the lysate of a human prostate cancer cell line (LNCaP), demonstrating the potential role of autologous DCs in prostate cancer immunotherapy

6/7/13 (Item 11 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 1999 BIOSIS. All rts. reserv.

09100767 BIOSIS NO.: 199497109137
Effect of post-thaw recovery time on the index of viability of **frozen**
/thawed **dendritic** cells: Comparison of two fluorescent membrane
integrity assays.

AUTHOR: Taylor M J
AUTHOR ADDRESS: Div. Cryobiol. and Hypothermic Med., Neurosci. Res. Cent.,
Allegheny-Singer Res. Inst., Allegheny Ge, USA

JOURNAL: Cryobiology 30 (6):p660-661 1993

CONFERENCE/MEETING: Thirtieth Annual Meeting of the Society for Cryobiology
Atlanta, Georgia, USA July 19-23, 1993

ISSN: 0011-2240

RECORD TYPE: Citation

LANGUAGE: English

6/7/20 (Item 18 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 1999 BIOSIS. All rts. reserv.

06919552 BIOSIS NO.: 000038059418
THE CRYOBIOLOGY OF RAT AND HUMAN **DENDRITIC** CELLS PRESERVATION AND
DESTRUCTION BY **FREEZING**

AUTHOR: TAYLOR M J; LONDON M J M; THIRDBOROUGH S T; LAKE S P; JAMES R F L
AUTHOR ADDRESS: MRC MED. CRYOBIOL. GROUP, DEP. SURG., CAMBRIDGE, ENGL., UK.

JOURNAL: TWENTY-SIXTH ANNUAL MEETING OF THE SOCIETY FOR CRYOBIOLOGY,
CHARLESTON, SOUTH CAROLINA, USA, JUNE 11-16, 1989. CRYOBIOLOGY 26 (6).
1989. 581.
CODEN: CRYBA
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation

6/7/40 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06893393 EMBASE No: 1997177773

A cryopreservation method of human peripheral blood mononuclear cells for efficient production of dendritic cells

Makino M.; Baba M.

Dr. M. Makino, Division of Human Retroviruses, Center for Chronic Viral Diseases, Fac. of Med., Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890 Japan

Scandinavian Journal of Immunology (SCAND. J. IMMUNOL.) (United Kingdom) 1997, 45/6 (618-622)

CODEN: SJIMA ISSN: 0300-9475

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 10

The establishment of a cryopreservation method for unstimulated fresh peripheral blood mononuclear cells (PBMC) with nearly 100% viability would greatly contribute to the conduct of various immunological experiments. The cells most sensitive to freezing and thawing procedure seem to be dendritic cells (DC) and their precursors, which are of the most potent antigen-presenting cells. The authors investigated and established a method of cryopreserving fresh PBMC from which DC were recovered and differentiated efficiently by using recombinant (r) GM-CSF and rIL-4. PBMC frozen in the presence of 12% dimethylsulfoxide and 25-30% fetal calf serum recovered DC as efficiently as freshly obtained PBMC. Established DC could also be cryopreserved in the presence of 12% DMSO with their viability maintained at more than 90%. The 12% DMSO freezing solutions were superior to both the 10% DMSO solution and the previously reported DC freezing medium (2 M or 15.4% DMSO). The DC obtained from the cryopreserved PBMC expressed HLA-DR, HLA-DQ, CD80 and CD86 antigens, and stimulated allogenic PBMC to an extent almost identical to that obtained from fresh PBMC. These findings indicate that the conditioned medium utilized here enables safe